Moreover, Rodig et al. (Rodig et al., 2018) demonstrated that loss of HLA expression might influence immune checkpoint blockade responses; specifically, the initial response to anti-CTLA-4 required MHC-I–mediated antigen presentation, whereas intact expression of tumor-specific MHC-II molecules was needed for the anti-PD-1 response in melanoma. The gene discussed is CTLA4; the disease is melanoma.